Testing PRO-1562 capsules in healthy adults and adults with relapsing multiple sclerosis
Tests PRO-1562 in healthy adults and adults with relapsing multiple sclerosis.
Plain-language title generated from the registry record
Registry title: A Phase 1/2a Study of Oral PRO-1562 in Healthy Subjects and Patients With Relapsing Multiple Sclerosis
Key facts
- Where
- Adelaide, AustraliaSee the site
- Phase
- Phase 1/2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07826689, who can take part
Where in Australia
- CMAX Clinical ResearchAdelaide, AustraliaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Progentos Therapeutics
- Trial code
- NCT07826689
- Record updated
- 29 September 2026
- Original description
Phase 1 will test single oral doses of PRO-1562 in healthy adult subjects to characterize the safety and the amount of drug that is absorbed into the body. Some subjects will have lumbar punctures performed to measure the amount of drug that crosses the blood-brain barrier since that is the site of drug activity.Read full original descriptionShow less
A Randomized, Double-Blind, Placebo-Controlled Phase 1/2a Trial of PRO-1562 in Healthy Adults and Adults With Multiple Sclerosis and Chronic Optic Neuropathy
Phase 1 will test single oral doses of PRO-1562 in healthy adult subjects to characterize the safety and the amount of drug that is absorbed into the body. Some subjects will have lumbar punctures performed to measure the amount of drug that crosses the blood-brain barrier since that is the site of drug activity.
Phase 2a will be a 6-month trial to test the ability of once monthly dosing of PRO-1562 to promote remyelination of the CNS and provide clinical benefit to adult patients with relapsing multiple sclerosis (RMS) who also have long-term vision problems diagnosed as chronic optic neuropathy. The benefits of remyelination will be measured using tests of visual acuity, speed of optic nerve conduction signals, and clinical assessments of cognitive and motor function. PRO-1562 will be added on to a stable regimen of MS disease modifying therapy.
Phase 1 Inclusion Criteria:; Able and willing to provide written informed consent; Body weight ≥ 48 kg (105.6 lbs) and body mass index (BMI) ≥ 18.5 and ≤ 30 kg/m2; Must be in good health and without clinically significant abnormalities by review of medical and surgical history, physical examination, vital signs measurement, and 12-lead ECG; No clinically-significant laboratory abnormalities; Willing and able to use highly-effective forms of contraception for at least 30 days after the end of study visit; Phase 1 Exclusion Criteria:; Ongoing medical condition requiring systemic therapy; Ongoing infection; mRNA or live vaccine during the past 60 days; History of significant hypersensitivity, intolerance, or allergy to any drug/medication; Participation in another clinical trial with an investigational agent within 30 days prior to Check-in or 5 half-lives (if known) of the investigational drug's PK, PD, or biological activity (if known), whichever is longer; Positive alcohol breath test or urine screen for drugs of abuse; Use or intent to use natural products or nutritional/dietary supplements (including St. John's wort), vitamins, minerals, and phytotherapeutic /herbal/plant-derived preparations within or received within 14 days or 5 half-lives prior to Check-in, whichever is longer; Poor peripheral venous access; Receipt of blood products within 2 months prior to Check-in; Donation of blood or blood products during the 4 weeks prior to Check-in; Participants who in the opinion of the Principal Investigator (or designee), should not participate in this study.